Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

GLP-1RA medications may increase the risk of hair loss, especially in non-diabetic people.

This study found that GLP-1 receptor agonists show potential for improving psoriasis and hidradenitis suppurativa by reducing inflammation and lesion severity, but they also pose dermatological risks such as alopecia and injection site reactions.

This study found that self-monitoring blood pressure among pregnant women with hypertension did not significantly improve clinical outcomes compared to usual care, though women reported positive cognitive and emotional responses.

In this retrospective case series, therapeutic responses to immunomodulatory and incretin-based therapies for Dercum's disease showed considerable individual variation, suggesting these treatments might be exploratory options when surgery isn't feasible, though further controlled studies are needed for definitive conclusions.

In this study, patient-reported outcomes indicated that greater weight loss with GLP-1RA treatments was associated with increased reports of adverse cosmetic effects such as skin laxity, facial volume loss, and hair shedding, despite improvements in some preexisting inflammatory skin conditions.

This review found no evidence that medications used to manage PCOS add to cardiovascular risk or prevent diabetes onset, although metformin may help prevent gestational diabetes in these patients.

This review examines current evidence on personalized management strategies for PCOS, but does not present new clinical results; the authors advocate for treatments tailored to predominant symptoms and individual health profiles.

This study found that glucagon-like peptide-1 receptor agonist therapy was independently associated with an increased incidence of non-scarring hair loss, including telogen effluvium and androgenic alopecia, in adults but not alopecia areata.

This review discusses current pharmacological and non-pharmacological treatment strategies for PCOS, emphasizing the need for a personalized, multimodal approach due to incomplete understanding of the syndrome's pathogenesis.

This study reviews current treatments for PCOS and evaluates Tirzepatide as a potential option for its management, suggesting possible benefits for those with obesity and metabolic syndrome but not for those of normal weight.

This study found that while glucagon-like peptide 1 receptor agonists report more incidents of suicide, hair loss, and aspiration compared to some other antidiabetic drugs, they did not meet the threshold for positive safety signals.

Tailored medication preparation and ongoing education are crucial for effective treatments.

This summary of a pharmacy internship reports on expanding scientific knowledge through diverse activities, including exploring diabetes medications for obesity treatment and discussing the role of nutritional supplements in geriatrics.

This book discusses current research on polycystic ovary syndrome, including diagnosis, management, and the impact of lifestyle changes, without reporting new clinical results.

This narrative review reports that metformin, traditionally used for type 2 diabetes management, may offer therapeutic benefits for various skin disorders, such as acne, rosacea, and psoriasis, due to its anti-inflammatory and other beneficial properties, warranting further exploration in dermatology.

This study suggests that sodium-glucose cotransporter-2 inhibitors, alone or with metformin or GLP1RA, may improve metabolic and hormonal parameters in women with polycystic ovary syndrome.

This book reviews the symptoms, diagnosis, and treatments for Polycystic Ovary Syndrome, providing a comprehensive exploration but reports no new clinical results.

Continuous glucose monitoring and GLP-1 receptor agonists improve diabetes management, but personalized care and education are crucial.

This study analyzed safety data for semaglutide, liraglutide, and tirzepatide from the EudraVigilance database, identifying potential safety signals not listed in current SmPCs, such as optic ischemic neuropathy and pancreatitis, underscoring the importance of ongoing pharmacovigilance.

In this review, researchers provided a comprehensive analysis of anti-androgen therapies for polyendocrine metabolic ovarian syndrome (PMOS/PCOS), examining their efficacy and safety while proposing a phenotype-guided management framework and highlighting research gaps, such as long-term cardiovascular safety and predictive biomarkers.

This study found that skin changes in morbidly obese individuals are associated with underlying metabolic disturbances but are not currently valuable as independent tools for assessing metabolic risk or treatment response.

GLP-1 receptor agonists may help or harm hair health, needing more research.

This review explores current and emerging treatments for polycystic ovary syndrome, focusing on managing hyperandrogenism and cardiometabolic risk, but reports no new clinical results.

This review discusses the relationship between gut microbiota and polycystic ovarian syndrome (PCOS), including its potential mechanisms and the role of alterations in microbiome composition on PCOS pathophysiology.

This review examined mechanisms regulating muscle repair, highlighting disruptions in aging and chronic diseases like Duchenne muscular dystrophy and diabetes. It noted that chronic inflammation and metabolic dysfunction hinder effective regeneration and discussed emerging therapies, suggesting multi-target approaches could be promising despite limited clinical evidence.

This study found that using renin-angiotensin system-targeting antihypertensive agents or statins is associated with reduced serum HER2 levels, which may influence the risk of metabolic syndrome in women.

This study confirmed that methimazole use is associated with agranulocytosis, pyrexia, exposure during pregnancy, and hyperthyroidism, while also identifying new safety signals like premature birth and septic shock that require further investigation.

This review reports that sex-related differences in pharmacological response have been observed in SARS-CoV-2 infection, dyslipidemia, and diabetes mellitus, with implications for treatment strategies; for example, men may respond better to genomic vaccines for SARS-CoV-2, while women may benefit more from certain antiviral medications.

This study discusses the rising interest in drug repositioning, particularly in response to COVID-19, and highlights various computational and experimental approaches used for repurposing existing drugs across different diseases, including rare conditions and chronic kidney disease.

This study found that adults with type 2 diabetes or obesity using semaglutide and tirzepatide experienced higher odds of nonscarring alopecia, such as telogen effluvium, compared to those using other GLP-1 receptor agonists, with hair loss potentially linked to physiologic stress from weight loss.